{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:54:48Z","timestamp":1777445688451,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prader-Willi syndrome (PWS) is a complex, multi-system, neurodevelopmental disorder characterised by neonatal muscular hypotonia, short stature, high risk of obesity, hypogonadism, intellectual disabilities, distinct behavioural\/psychiatric problems and abnormal body composition with increased body fat and a deficit of lean body mass. Growth hormone (GH) deficiency and other hormone deficiencies are common due to hypothalamic dysfunction. In children with PWS GH treatment has been widely demonstrated to improve body composition, normalise height and improve psychomotor development. In adults with PWS, GH\u2019s main effects are to maintain normal body structure and metabolism. The positive effects of GH treatment on body composition, physical fitness and beneficial effects on cardiovascular risk markers, behaviour and quality of life in adults with PWS are also well established from several studies. GH treatment is approved for treatment of children with PWS in many countries, but until recently not as a treatment in young adults in the transition period or for adults in general. In this commentary we want to draw attention to the uneven global use of GH treatment, specifically in adults with PWS, and advocate for GH treatment to be approved internationally, not just for children, but also for adults with PWS and based only on the diagnosis of genetically confirmed PWS.<\/jats:p>","DOI":"10.1186\/s13023-020-01651-x","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T22:44:17Z","timestamp":1612824257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Time for a general approval of growth hormone treatment in adults with Prader\u2013Willi syndrome"],"prefix":"10.1186","volume":"16","author":[{"name":"The Clinical and Scientific Advisory Board of The International Prader-Willi Syndrome Organisation","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"H\u00f6ybye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9612-773X","authenticated-orcid":false,"given":"Daniel J.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"1651_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-020-01440-6","volume":"15","author":"L Damen","year":"2020","unstructured":"Damen L, Donze SH, Kuppens RJ, Bakker NE, de Graaff LCG, van der Velden AEM, Hokken-Koelega ACS. Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition. Orphanet J Rare Dis. 2020;15:163. https:\/\/doi.org\/10.1186\/s13023-020-01440-6.","journal-title":"Orphanet J Rare Dis"},{"key":"1651_CR2","unstructured":"Driscoll DJ, Miller JL, Schwartz S, et al. Prader-Willi Syndrome. 1998 Oct 6 [Updated 2017 Dec 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1330\/"},{"key":"1651_CR3","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1210\/jc.2008-0649","volume":"93","author":"AP Goldstone","year":"2008","unstructured":"Goldstone AP, Holland AJ, Hauffa BP, et al. Recommendations for the diagnosis and management of Prader\u2013Willi syndrome. J Clin Endocrinol Metab. 2008;93:4183\u201397.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1651_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","volume":"155A","author":"JL Miller","year":"2011","unstructured":"Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader\u2013Willi syndrome. Am J Med Genet. 2011;155A(5):1040\u20139.","journal-title":"Am J Med Genet"},{"key":"1651_CR5","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:3888.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1651_CR6","doi-asserted-by":"publisher","first-page":"E1072","DOI":"10.1210\/jc.2012-3888","volume":"98","author":"CL Deal","year":"2013","unstructured":"Deal CL, Tony M, Hoybye C, et al. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader\u2013Willi syndrome. J Clin Endocrinol Metab. 2013;98(6):E1072-1087.","journal-title":"J Clin Endocrinol Metab"},{"key":"1651_CR7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/TCRM.S70068","volume":"12","author":"G Grugni","year":"2016","unstructured":"Grugni G, Sattorio A, Crino A. Growth hormone therapy for Prader\u2013Willi syndrome: challenges and solutions. Ther Clin Risk Manag. 2016;12:873\u201381.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"1651_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2265.2011.04303.x","volume":"77","author":"R Sanchez-Ortiga","year":"2012","unstructured":"Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader\u2013Willi syndrome: a meta-analysis. Clin Endocrinol (Oxf). 2012;77(1):86\u201393.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1651_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ghir.2011.05.002","volume":"21","author":"R Sode-Carlsen","year":"2011","unstructured":"Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Frystyk J, Christiansen JS, H\u00f6ybye C. Growth hormone treatment for two years is safe and effective in adults with Prader\u2013Willi syndrome. Growth Horm IGF Res. 2011;21(4):185\u201390.","journal-title":"Growth Horm IGF Res"},{"key":"1651_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1651-2227.2006.00051.x","volume":"96","author":"C H\u00f6ybye","year":"2007","unstructured":"H\u00f6ybye C. Five years growth hormone (GH) treatment in adults with Prader\u2013Willi syndrome. Acta Paediatr. 2007;96:410\u20133.","journal-title":"Acta Paediatr"},{"issue":"4","key":"1651_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/apa.12898","volume":"104","author":"C H\u00f6ybye","year":"2015","unstructured":"H\u00f6ybye C. Fifteen years of growth hormone treatment in men with Prader\u2013Willi Syndrome. Acta Paediatr. 2015;104(4):422\u20137.","journal-title":"Acta Paediatr"},{"issue":"11","key":"1651_CR12","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1210\/jc.2016-2594","volume":"101","author":"RJ Kuppens","year":"2016","unstructured":"Kuppens RJ, Bakker NE, Siemensma EP, et al. Beneficial effects of GH in young adults with Prader\u2013Willi syndrome: a 2-year crossover trial. J Clin Endocrinol Metab. 2016;101(11):4110\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1651_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1507\/endocrj.EJ18-0107","volume":"65","author":"M Koizumi","year":"2018","unstructured":"Koizumi M, Ida S, Shoji Y, Nishimoto Y, Etani Y, Kawai M. Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader\u2013Willi syndrome. Endocr J. 2018;65(11):1127\u201337.","journal-title":"Endocr J"},{"key":"1651_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2788.2005.00641.x","volume":"49\u20134","author":"C H\u00f6ybye","year":"2005","unstructured":"H\u00f6ybye C, Thor\u00e9n M, B\u00f6hm B. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader\u2013Willi syndrome. J Intellect Disabil Res. 2005;49\u20134:245\u201352.","journal-title":"J Intellect Disabil Res"},{"issue":"9","key":"1651_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/BF03349255","volume":"31","author":"LA Gondoni","year":"2008","unstructured":"Gondoni LA, Vismara L, Marzullo P, Vettor R, Liuzzi A, Grugni G. Growth hormone therapy improves exercise capacity in adult patients with Prader\u2013Willi syndrome. J Endocrinol Invest. 2008;31(9):765\u201372.","journal-title":"J Endocrinol Invest"},{"key":"1651_CR16","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1210\/jc.2013-3607","volume":"99","author":"CL Lafortuna","year":"2014","unstructured":"Lafortuna CL, Minocci A, Capodaglio P, Gondoni LA, Sartorio A, et al. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with Prader\u2013Willi syndrome. J Clin Endocrinol Metab. 2014;99:1816\u201324.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1651_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/cen.13567","volume":"88","author":"SH Donze","year":"2018","unstructured":"Donze SH, Kuppens RJ, Bakker NE, van der Velden JAEM, Hokken-Koelega ACS. Bone mineral density in young adults with Prader\u2013Willi syndrome: a randomized, placebo-controlled, crossover GH trial. Clin Endocrinol (Oxf). 2018;88(6):806\u201312.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"4","key":"1651_CR18","doi-asserted-by":"publisher","first-page":"E753","DOI":"10.1210\/jc.2012-3378","volume":"98","author":"AP J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen AP, Ueland T, Sode-Carlsen R, Schreiner T, Rabben KF, Farholt S, H\u00f8ybye C, Christiansen JS, Bollerslev J. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD. J Clin Endocrinol Metab. 2013;98(4):E753\u201360.","journal-title":"J Clin Endocrinol Metab"},{"key":"1651_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1365-2788.2006.00878.x","volume":"51","author":"L Bertella","year":"2007","unstructured":"Bertella L, Mori I, Grugni G, Pignatti R, Ceriani F, Molinari E, Ceccarelli A, Sartorio A, Vettor R, Semenza C. Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study. J Intellect Disabil Res. 2007;51:302\u201311.","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"1651_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-016-0535-7","volume":"11","author":"RJ Kuppens","year":"2016","unstructured":"Kuppens RJ, Mahabier EF, Bakker NE, Siemensma EP, Donze SH, Hokken-Koelega AC. Effect of cessation of GH treatment on cognition during transition phase in Prader\u2013Willi syndrome: results of a 2-year crossover GH trial. Orphanet J Rare Dis. 2016;11(1):153.","journal-title":"Orphanet J Rare Dis"},{"key":"1651_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01450-y","author":"G Grugni","year":"2020","unstructured":"Grugni G, Marzullo P, Delvecchio M, et al. Stimulated GH levels during the transition phase in Prader\u2013Willi syndrome. J Endocrinol Invest. 2020. https:\/\/doi.org\/10.1007\/s40618-020-01450-y.","journal-title":"J Endocrinol Invest"},{"key":"1651_CR22","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1210\/clinem\/dgz149","volume":"105","author":"BS Miller","year":"2020","unstructured":"Miller BS, Velazquez E, Yuen K. Long-acting growth hormone preparations-current status and future considerations. J Clin Endocrinol Metab. 2020;105:2121\u201333.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01651-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-01651-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01651-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T22:50:32Z","timestamp":1612824632000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01651-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01651-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors are members of the Clinical and Scientific Advisory Board of IPWSO and declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}